ESC 2025: Acoramidis may reduce AF/flutter burden in ATTR-CM, per new ATTRibute-CM trial analysis discussed by CardioNerds.
Expert Interviews
Advertisement
BMAL1-HIF2α link explains why AM heart attacks hit harder—new findings may lead to time-based cardioprotective therapies.
AI-driven ECGs are transforming heart failure care—enabling early detection, cutting costs, and expanding access.
Dr. Payal Kohli dives into new tech and AI reshaping how we diagnose and manage hypertension.
Hypertension isn’t just a part of aging—lifestyle, awareness, and new treatments matter.
Dr. Daniel Judge discusses how the ATTRibute-CM trial marks a turning point in ATTR cardiomyopathy treatment and research.
Dr. Dan Judge speaks to The CardioNerds about his interpretation of the primary findings from ATTRibute-CM.
Dr. Daniel Judge talks to the CardioNerds about a pivotal study in ATTR-CM.
Dr. Kevin Alexander speaks with The CardioNerds about the importance of providing swift treatment to patients with ATTR-CM.
The CardioNerds, Dr. Alexander discuss how acoramidis therapy works, and details data Dr. Alexander presented at AHA 2024.
Dr. Georgia Vasilakis Tsatiris of The CardioNerds speaks to Dr. Kevin Alexander about the impact of ATTR-CM.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.